Interventions for treating collagenous colitis

Chande, Nilesh; McDonald, JWD; MacDonald, JK

doi:10.1002/14651858.cd003575.pub4

Cited by 14 publications

(12 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with previous studies the stool frequency decreased significantly during the budesonide treatment. 18 With reduced symptoms and hence less diarrhoea a greater part of the tracer would be retained in the colon which may increase the 75 SeHCAT values even if the ileal uptake of BAs is unchanged. However, previous studies suggest that the major contribution to the 75 SeHCAT retention values on day 7 originates from the enterohepatic circulation even if the diarrhoea has ceased.…”

Section: Discussionmentioning

confidence: 99%

“…Because of the high response to treatment with BA-binding resins irrespective of BA malabsorption and the very high response to budesonide treatment we included all patients with collagenous colitis. [7][8][9]18 To further highlight the role of BAs in this disease a study in a subgroup of patients with concomitant BA malabsorption is demanded.…”

Section: Discussionmentioning

confidence: 99%

“…According to a Cochrane database systematic review most evidence is accumulated for the efficacy of budesonide in the treatment of collagenous colitis. 18 Budesonide is a corticosteroid designed to achieve a topical effect in the terminal ileum and proximal colon. 19 The mechanism behind the often dramatic improvement of the symptoms by budesonide treatment seen in this disease localized to the colon is still unknown.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Budesonide treatment is associated with increased bile acid absorption in collagenous colitis

Bajor

Kilander

Gälman

et al. 2006

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Budesonide treatment is associated with increased bile acid absorption in collagenous colitis

Bajor

Kilander

Gälman

et al. 2006

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Insofar, the treatment with budesonide looks promising, however, the evidence for benefit with bismuth subsalicylate is weaker. Moreover, the effectiveness of prednisolone, Boswellia serrata extract and other therapies for induction or maintenance of remission of colitis is unknown and requires further study (Chande et al 2006). …”

Section: Various Gi Diseases and Their Treatment Limitationsmentioning

confidence: 99%

Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells

Prakash

Urbanska²

2008

BTT

View full text Add to dashboard Cite

There has been an ample interest in delivery of therapeutic molecules using live cells. Oral delivery has been stipulated as best way to deliver live cells to humans for therapy. Colon, in particular, is a part of gastrointestinal (GI) tract that has been proposed to be an oral targeted site. The main objective of these oral therapy procedures is to deliver live cells not only to treat diseases like colorectal cancer, inflammatory bowel disease, and other GI tract diseases like intestinal obstruction and gastritis, but also to deliver therapeutic molecules for overall therapy in various diseases such as renal failure, coronary heart disease, hypertension, and others. This review provides a comprehensive summary of recent advancement in colon targeted live bacterial cell biotherapeutics. Current status of bacterial cell therapy, principles of artificial cells and its potentials in oral delivery of live bacterial cell biotherapeutics for clinical applications as well as biotherapeutic future perspectives are also discussed in our review.

show abstract

“…Furthermore, somewhat weaker evidence exists for the use of bismuth subsalicylate (PeptoBismol®, Procter & Gamble, Cincinnati, OH; nine 262 mg tablets taken daily over a period of 8 weeks) to treat collagenous colitis. 14 …”

Section: Treatmentmentioning

confidence: 99%

Non-IBD and noninfectious colitis

Nielsen

Vainer

Rask-Madsen

2008

Nat Rev Gastroenterol Hepatol

View full text Add to dashboard Cite

A wide range of etiologies and pathogenic mechanisms underlie colitis. This Review provides an overview of the pathophysiology, epidemiology, histopathology, and clinical characteristics of noninfectious and non-IBD forms of colitis: microscopic colitis, Behçet's syndrome, diversion colitis, diverticular colitis, eosinophilic colitis, ischemic colitis, and radiation colitis. These more recently characterized and rare forms of colitis occur as either primary conditions or complications of other diseases. Most of these diseases are uncommon; therefore, epidemiologic data and data from controlled trials are not readily available. Practical guidelines for the diagnosis and therapy of these more recently characterized and rarer forms of colitis are given where possible.

show abstract

Interventions for treating collagenous colitis

Cited by 14 publications

References 61 publications

Budesonide treatment is associated with increased bile acid absorption in collagenous colitis

Budesonide treatment is associated with increased bile acid absorption in collagenous colitis

Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells

Non-IBD and noninfectious colitis

Contact Info

Product

Resources

About